Composite gangliocytoma/neuroma and neuroendocrine tumor: a clinicopathologic, immunohistochemical, and molecular genetic study of 11 cases. 2025

M Lisa Zhang, and David M Meredith, and Andrew M Bellizzi, and Jonathan A Nowak, and David J Papke
Department of Pathology, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA.

Composite gangliocytoma/neuroma and neuroendocrine tumor (CoGNET, previously "gangliocytic paraganglioma"), is a rare tumor type of uncertain pathogenesis in the ampulla/periampullary duodenum. Here, we present 11 CoGNETs in 6 females (55%) and 5 males (median age: 55 years; range: 28-69 years), all in the ampulla or duodenum. Tumors were triphasic with variable proportions of (1) neuroendocrine nests, (2) spindle cell nerve sheath regions, and (3) ganglion-like cells. By immunohistochemistry, ganglion-like cells expressed broad-spectrum keratins, somatostatin, NFP, and islet-1, and they lacked expression of PHOX2B. Neuroendocrine nests diffusely expressed ARX, islet-1, pancreatic polypeptide, and somatostatin, and they lacked expression of CDX2 and PDX1. Spindle cells expressed NFP and S-100. Targeted DNA sequencing of four tumors demonstrated 15q loss in two and multiple copy number alterations in one. Whole-exome DNA sequencing of five tumors showed borderline evidence of an NF1 frameshift mutation in one. Clinical follow-up was available for 8 patients (73%; median length: 7.0 years; range: 1.3 months-13.9 years). One Whipple resection showed regional lymph node metastases in a patient who remained disease-free 12.3 years later. No patients experienced recurrence or metastasis following surgery. The expression pattern of endocrine hormones and transcription factors distinguished CoGNET from other pancreatic and duodenal neuroendocrine tumor subtypes. The ganglion-like cells expressed keratins and not PHOX2B, demonstrating immunophenotypic divergence from true ganglion cells. Therefore, we propose that alternative nomenclature "gangliocytoid neuroendocrine neoplasm" or "composite gangliocytoid neuroendocrine neoplasm" be considered. The relative lack of pathogenic mutations raises the possibility that these tumors might harbor epigenetic drivers.

UI MeSH Term Description Entries

Related Publications

M Lisa Zhang, and David M Meredith, and Andrew M Bellizzi, and Jonathan A Nowak, and David J Papke
May 2024, Zhonghua bing li xue za zhi = Chinese journal of pathology,
M Lisa Zhang, and David M Meredith, and Andrew M Bellizzi, and Jonathan A Nowak, and David J Papke
May 2007, The American journal of surgical pathology,
M Lisa Zhang, and David M Meredith, and Andrew M Bellizzi, and Jonathan A Nowak, and David J Papke
April 2005, Brain pathology (Zurich, Switzerland),
M Lisa Zhang, and David M Meredith, and Andrew M Bellizzi, and Jonathan A Nowak, and David J Papke
July 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
M Lisa Zhang, and David M Meredith, and Andrew M Bellizzi, and Jonathan A Nowak, and David J Papke
August 2025, Histopathology,
M Lisa Zhang, and David M Meredith, and Andrew M Bellizzi, and Jonathan A Nowak, and David J Papke
May 2017, The American journal of surgical pathology,
M Lisa Zhang, and David M Meredith, and Andrew M Bellizzi, and Jonathan A Nowak, and David J Papke
February 2018, Human pathology,
M Lisa Zhang, and David M Meredith, and Andrew M Bellizzi, and Jonathan A Nowak, and David J Papke
July 2004, Human pathology,
M Lisa Zhang, and David M Meredith, and Andrew M Bellizzi, and Jonathan A Nowak, and David J Papke
September 2024, Journal of neuropathology and experimental neurology,
M Lisa Zhang, and David M Meredith, and Andrew M Bellizzi, and Jonathan A Nowak, and David J Papke
August 2003, American journal of clinical pathology,
Copied contents to your clipboard!